Arvinas (NASDAQ:ARVN - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.44, Zacks reports. During the same quarter in the prior year, the business posted ($2.53) earnings per share.
Arvinas Stock Up 2.0 %
ARVN traded up $0.35 during trading hours on Friday, hitting $18.02. The stock had a trading volume of 573,615 shares, compared to its average volume of 901,601. Arvinas has a 1 year low of $16.61 and a 1 year high of $53.08. The company's fifty day simple moving average is $19.04 and its 200 day simple moving average is $23.28. The stock has a market cap of $1.24 billion, a PE ratio of -3.86 and a beta of 1.88.
Wall Street Analyst Weigh In
Several research firms recently weighed in on ARVN. BMO Capital Markets restated an "outperform" rating and set a $82.00 price target (down from $88.00) on shares of Arvinas in a report on Wednesday. Stephens initiated coverage on Arvinas in a research note on Monday, November 18th. They issued an "overweight" rating and a $55.00 target price on the stock. Stifel Nicolaus decreased their price target on Arvinas from $63.00 to $51.00 and set a "buy" rating for the company in a research report on Wednesday. BTIG Research began coverage on Arvinas in a report on Tuesday, December 10th. They set a "buy" rating and a $69.00 price target on the stock. Finally, Guggenheim restated a "buy" rating and issued a $57.00 price objective on shares of Arvinas in a research note on Wednesday. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $59.58.
Get Our Latest Report on ARVN
About Arvinas
(
Get Free Report)
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Read More
Before you consider Arvinas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arvinas wasn't on the list.
While Arvinas currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
